Skip to main content
. 2024 Aug 2;27(9):110634. doi: 10.1016/j.isci.2024.110634

Figure 4.

Figure 4

Evaluation of AE signature on ICI combination therapy not seen by the model during training

Kaplan-Meier plots for OS, per treatment arm (durvalumab + tremelimumab vs. chemotherapy) and signature class, for MYSTIC trial data landmarked at 60 days. sig, ML AE signature.